- Aliath Bioventures, part of AltamarCAM Partners, is the groups’ life sciences impact investment business.
- The firm also reinforces the life sciences team with the appointment of Joana Correia as a senior analyst that join Beatriz Gandarias, Jose Maria Fernández and the Alta Life Sciences team
Madrid, 19th of September 2023.- Aliath Bioventures, the healthcare impact investment platform of AltamarCAM Partners, appoints Philippe Monteyne, MD, PhD as a new Partner to reinforce the company’s healthcare investment team. As of 16th November 2023, Philippe Monteyne will join the team responsible for Alta Life Sciences Spain I FCR and the newly launched, ACP Aliath Bioventures II FCR (ABV II), specialised in investing in companies in the healthcare sector and that has been registered as an article 9 fund under the Sustainable Finance Disclosure Regulation (SFDR).
Philippe Monteyne has extensive and highly successful experience as a life sciences investor and pharmaceutical professional. For the past eight years, Philippe has been a Senior Partner of the private equity fund Fund+ in Belgium, having contributed to multiple investments including very profitable ones such as Ogeda and Iteos. Previously he held senior positions in the pharmaceutical industry, such as Vice President R&D France at Sanofi and Global Head of Vaccine Development at GlaxoSmithkline, where he led the development of the Cervarix vaccine for cervical cancer. He has also been responsible for global and medical development of the orphan disease business of GSK.
Philippe is a Neurologist and holds a PhD in viral immunology from the Catholic University of Louvain and a postdoctoral degree in neuroimmunology from the Pasteur Institute in Paris. In addition, Philippe has been a member of the Board of Directors of Sanofi Aventis R&D, of the LEEM (French pharmaceutical association “Les Entreprises du Médicament”), of the Institute for Research in Technology (IRT) Bioaster in Lyon, of the Fondation “Plan Alzheimer France”, and of the Board of Directors of several Biotech companies in Belgium, France, and Spain.
“I am very excited to join Aliath Bioventures and support its plans to invest in innovative companies and its strategy focused on impact and sustainability. I have spent most of my career in the investment, healthcare and pharmaceutical sectors and I look forward to continuing this journey with a strong group of very talented professionals such as those at Aliath,” has said Philippe Monteyne.
Montse Vendrell Partner of Alta Life Sciences and Aliath Bioventures added: “We are delighted to welcome Philippe to our team. His extensive experience in the healthcare sector will help us deliver on our goal of generating value for our investors while also improving people’s health.”
José Luis Molina, Global CEO of AltamarCAM, stated: “The appointment of Philippe Monteyne marks a significant milestone for our Life Sciences business, and I am confident it will play a pivotal role in shaping the future of our impact investing initiatives in healthcare -a crucial and highly innovative sector for both society and the economy-”.
Joana Correia also joined the team at the beginning of September as a Senior Analyst, from Ysios. Joana holds a degree in Applied Biomedical Sciences from Middlesex University and a master’s degree in Nanotechnology and Regenerative Medicine from University College London and a Ph.D. in Biotechnology from Imperial College.
ABV II will mainly invest in European companies, with the possibility to make some investments outside of Europe. Its investments will be focused on companies operating in biotechnology and biopharma or related to health technologies companies. ABV II has been registered as an article 9 fund under the Sustainable Finance Disclosure Regulation (SFDR). This is AltamarCAM Partners’ second life sciences fund.
About Aliath Bioventures
Aliath aims to fund sustainable businesses that can create a significant impact on patients’ lives by providing new medical solutions and technologies that impact access, effectiveness and efficiency in the health sector. The Aliath team consists of experienced professionals with complementary backgrounds and skills including venture capital, operational, scientific, clinical and financial expertise. Aliath is part of the AltamarCAM group.
About AltamarCAM Partners
AltamarCAM Partners is a private asset manager and solutions provider offering institutional investors -insurance companies, pension funds and financial entities – together with high net worth individuals, access to global private asset investments: private equity, venture capital, life sciences, real assets (real estate and infrastructures) and private debt / credit, through its selection of international managers, and different strategies (primaries, secondaries, co-investments and direct investment).
Additionally, AltamarCAM provides independent investment banking and merchant banking services through its subsidiary Altamar Advisory Partners, as well as direct and efficient access to funds from a selection of international fund managers through its subsidiary Altamar Global Investments AV. With offices in Madrid, Cologne, Barcelona, New York, London, Santiago de Chile and Munich, it has a team of more than 250 people. AltamarCAM Partners has more than €18 billion in investment commitments from investors.
Media Contacts
Antonio Álvarez, Head of Communications (aalvarez@altamarcam.com)
Tel +34 646326483
Harmon (Abigail Diaz-Agero / Carlota Vicén) altamarcam@harmon.es
Tel + 34 689033562 / +34 609609547